A control systems analysis of HIV prevention model using impulsive input

We investigate a control systems analysis on HIV infection dynamics with regard to enhancement of the immune response. The HIV dynamic model is modified to include the pharmaco-kinetics and pharmacodynamics of antiretroviral HIV drugs, and the intake of drug is considered as impulsive control input. As it is administrated at discrete time instants, we assume that this yields an impulsive control problem for a nonlinear continuous-time system. Based on this new model, we study clinical experiments about antiretoviral treatments via numerical simulation and analyse the experimental results. It is noted that this modeling approach can help to provide a theoretical explanation of the clinical results. The analysis result in the paper could imply that the protocol of the experiment might enhance the immune response against HIV.

[1]  Hulin Wu,et al.  Modeling HIV dynamics and antiviral response with consideration of time-varying drug exposures, adherence and phenotypic sensitivity. , 2003, Mathematical biosciences.

[2]  Peter Vickerman,et al.  HIV Treatment as Prevention: Models, Data, and Questions—Towards Evidence-Based Decision-Making , 2012, PLoS medicine.

[3]  Ryan Zurakowski,et al.  A model predictive control based scheduling method for HIV therapy. , 2006, Journal of theoretical biology.

[4]  Louis Tong,et al.  Limited Knowledge and Use of HIV Post- and Pre-Exposure Prophylaxis Among Gay and Bisexual Men , 2008 .

[5]  Claude H. Moog,et al.  Impulsive control of single-input nonlinear systems with application to HIV dynamics , 2012, Appl. Math. Comput..

[6]  Sabine Yerly,et al.  Early and Prolonged Antiretroviral Therapy Is Associated with an HIV-1-Specific T-Cell Profile Comparable to That of Long-Term Non-Progressors , 2011, PloS one.

[7]  Alan S. Perelson,et al.  Mathematical Analysis of HIV-1 Dynamics in Vivo , 1999, SIAM Rev..

[8]  Tao Yang,et al.  Impulsive control , 1999, IEEE Trans. Autom. Control..

[9]  E Comets,et al.  An in vivo Pharmacokinetic/Pharmacodynamic Model for Antiretroviral Combination , 2003, HIV clinical trials.

[10]  Lin Shen,et al.  Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs , 2008, Nature Medicine.

[11]  Alessandro Astolfi,et al.  A control systems approach to HIV prevention with impulsive control input , 2012, 2012 IEEE 51st IEEE Conference on Decision and Control (CDC).

[12]  John T Brooks,et al.  Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. , 2012, The New England journal of medicine.

[13]  James D. Campbell,et al.  Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. , 2012, The New England journal of medicine.

[14]  D. Wodarz,et al.  Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. , 2001, Journal of theoretical biology.

[15]  David V Glidden,et al.  Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. , 2010, The New England journal of medicine.

[16]  Kenneth H Mayer,et al.  Preexposure Antiretroviral Prophylaxis Attitudes in High-Risk Boston Area Men Who Report Having Sex With Men: Limited Knowledge and Experience but Potential for Increased Utilization After Education , 2009, Journal of acquired immune deficiency syndromes.

[17]  C. Moog,et al.  Algebraic Methods for Nonlinear Control Systems , 2006 .

[18]  B. Adams,et al.  Dynamic multidrug therapies for hiv: optimal and sti control approaches. , 2004, Mathematical biosciences and engineering : MBE.

[19]  Malcolm Rowland,et al.  Clinical pharmacokinetics : concepts and applications , 1989 .

[20]  Hulin Wu,et al.  Hierarchical Bayesian inference for HIV dynamic differential equation models incorporating multiple treatment factors , 2010, Biometrical journal. Biometrische Zeitschrift.

[21]  M. Nowak,et al.  Virus dynamics: Mathematical principles of immunology and virology , 2001 .

[22]  Hyungbo Shim,et al.  A system theoretic study on a treatment of AIDS patient by achieving long-term non-progressor , 2009, Autom..

[23]  A. Perelson,et al.  Complex patterns of viral load decay under antiretroviral therapy: influence of pharmacokinetics and intracellular delay. , 2004, Journal of theoretical biology.

[24]  Lei Wang,et al.  Prevention of HIV-1 infection with early antiretroviral therapy. , 2011, The New England journal of medicine.

[25]  Antonios Armaou,et al.  An extracellular stochastic model of early HIV infection and the formulation of optimal treatment policy , 2008 .

[26]  Doug Taylor,et al.  Tenofovir Disoproxil Fumarate for Prevention of HIV Infection in Women: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Trial , 2007, PLoS clinical trials.

[27]  Lynn Morris,et al.  Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women , 2010, Science.

[28]  Wei Zhang,et al.  Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study. , 2011, Clinical therapeutics.

[29]  M A Nowak,et al.  The role of antigen-independent persistence of memory cytotoxic T lymphocytes. , 2000, International immunology.

[30]  Alessandro Astolfi,et al.  Activation of Immune Response in Disease Dynamics via Controlled Drug Scheduling , 2009, IEEE Transactions on Automation Science and Engineering.

[31]  Lin Shen,et al.  A Quantitative Basis for Antiretroviral Therapy for HIV-1 Infection , 2012, Nature Medicine.

[32]  Shuzhi Sam Ge,et al.  Nonlinear control of a dynamic model of HIV-1 , 2005, IEEE Transactions on Biomedical Engineering.

[33]  Lin Shen,et al.  Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance , 2011, Proceedings of the National Academy of Sciences.

[34]  David Back,et al.  Tenofovir, Emtricitabine Intracellular and Plasma, and Efavirenz Plasma Concentration Decay Following Drug Intake Cessation: Implications for HIV Treatment and Prevention , 2013, Journal of acquired immune deficiency syndromes.